Results 111 to 120 of about 557 (132)

In adults with overweight or obesity, weekly subcutaneous cagrilintide–semaglutide increased weight loss at 68 wk

Annals of Internal Medicine
GIM/FP/GP: [Formula: see text].
Arnav Agarwal, Raj Padwal
openaire   +2 more sources

2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice

Diabetes
Introduction and Objective: Cagrilintide is a long-acting amylin analogue currently in clinical development for the treatment of obesity, acting as a dual amylin and calcitonin receptor (CTR) agonist. While it produces robust body weight loss in humans, its effects are attenuated in mice, highlighting gaps in our understanding of its central mechanisms.
GRETA LOMMI, SIMONE VIGOLO, THOMAS A. LUTZ, CHRISTELLE LE FOLL   +3 more
openaire   +1 more source

Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis

Aim: To evaluate the efficacy and safety of the fixed-dose combination of cagrilintide and semaglutide (CagriSema) compared with semaglutide, cagrilintide, or placebo in adults with overweight or obesity, integrating current evidence from randomized controlled trials Methods: We ...
Miguel Angel Samaniego Laguna, Pedro Gomes-Batista, John Cedric Mojica, Marcela Vasconcelos Montenegro, Mrunalini Dandamudi, Juan Samaniego, Alejandro Barbagelata, Juliana Giorgi   +7 more
openaire   +1 more source

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression

Diabetes, Obesity and Metabolism
ABSTRACT Background Obesity is a complex chronic disease requiring effective long‐term management. We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
Muhammad Ahmed, Muhammad Hassan, Muhammad Tahir, Muhammad Hussain, Faisal Islam, Ghulam Taha Khan, Muhammad Ahsan, Shaheer Bin Shafiq, Ahmed Ibrahim, Ammad Uddin, Saad Ahmed Waqas   +10 more
openaire   +2 more sources

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Lancet, The, 2021
Altynai Satylganova
exaly  

Cellular loci for cagrilintide action identified

Nature Metabolism
Zsofia Hevesi, Tibor Harkany
openaire   +1 more source

Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models

Biomedicine and Pharmacotherapy, 2022
K Henriksen
exaly  

Neues Mittel Cagrilintid boostert Semaglutid

MMW - Fortschritte der Medizin
openaire   +1 more source

Stärkere Gewichtsreduktion durch Cagrilintid plus Semaglutid

CardioVasc
openaire   +1 more source

Cagrilintide–semaglutide: a new option for patients with type 2 diabetes

The Lancet Diabetes & Endocrinology
openaire   +1 more source